Singapore, Feb. 25 -- US-based Sarepta Therapeutics, Inc. has announced the commercial launch of ELEVIDYS (delandistrogene moxeparvovec) in Japan by Chugai Pharmaceutical, following its reimbursement listing on Japan's National Health Insurance (NHI) price list.

Elevidys is the first gene therapy to be launched in Japan for Duchenne muscular dystrophy (DMD). In Japan, ELEVIDYS is available for ambulatory individuals with Duchenne ages 3-to less than 8-years-old, a deletion of any portion or the entirety of exon 8 and/or exon 9 in the DMD gene, and who are negative for anti-AAVrh74 antibodies.

Chugaiannouncedthat ELEVIDYS has been launched in Japan following reimbursement listing, enabling access for eligible patients under the condition...